Lenalidomide Zentiva (Lenalidomide)

Lenalidomide is an immunomodulatory antineoplastic that targets malignant plasma cells and dysplastic bone‑marrow clones.

• Multiple myeloma: helps control disease progression and improve survival in patients who have received prior therapy.
• Myelodysplastic syndromes: reduces transfusion dependence and may modify disease course in patients with del(5q) cytogenetic abnormality.

• Lenalidomide exerts its antitumor activity by binding to cereblon, a component of the E3 ubiquitin ligase complex, leading to degradation of transcription factors Ikaros and Aiolos. This results in inhibition of angiogenesis, modulation of cytokine production, and enhancement of natural killer and T‑cell mediated immune responses against malignant cells.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Thrombocytopenia: lowered platelet count causing bleeding tendency.
• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may lead to dehydration.
• Constipation: difficulty passing stools.
• Rash: mild skin irritation or redness.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Severe neutropenia: profound immune suppression requiring medical intervention.
• Hepatotoxicity: liver enzyme elevations indicating possible liver injury.
• Secondary malignancies: emergence of new cancers during treatment.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac arrhythmias: irregular heart rhythms in susceptible patients.

Patients receiving Lenalidomide should be monitored closely for safety concerns.

• Blood monitoring: regular complete blood counts to detect cytopenias.
• Thrombotic risk assessment: evaluate need for prophylactic anticoagulation.
• Pregnancy avoidance: enforce strict contraception due to teratogenic potential.
• Renal function: adjust therapy in patients with impaired kidney function.
• Drug interaction review: assess concomitant medications for potential interactions.
• Store at room temperature: keep in original container, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of thromboembolic events.
• Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug effectiveness.
• NSAIDs: potential additive effect on platelet inhibition.
• Antihypertensives: monitor blood pressure as lenalidomide can cause fluid shifts.